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Abstract 
BACKGROUND: Curcumin is a major component in curcuminoid which acts as an anti-inflammatory agent. 
Curcumin affects several biological markers that are thought to play a role in the pathogenesis of preeclampsia 
such as IL-10 and COX-2, resulting in an improvement in pregnant women with preeclampsia.  
AIM: To see the effect of perioperative curcumin administration on IL-10 and COX-2 in preeclamptic patients 
undergoing caesarean section under spinal anaesthesia.  
METHODS: This study was a double-blind, randomised clinical trial conducted at Pirngadi Hospital, USU Hospital 
and Sundari General Hospital Medan as a hospital network of Faculty of Medicine, North Sumatra University. 
Group 1 received a drug containing curcumin (as a treatment), and another group received a placebo (as a 
control).  
RESULTS: There were no significant differences in the median values of COX-2 and IL-10 before and after 
treatment and also the p-values were greater than 0.05 in both groups (control and treatment).  
CONCLUSION: There is no significant difference between the use of curcumin on serum COX-2 and IL-10 levels. 
 
 
 
 
 
 
 
 
 
Introduction 
 
Preeclampsia is a disorder in pregnant 
women with a gestational age of 20 weeks or more 
which characterised by hypertension and proteinuria 
that occurs in 5-10% of pregnancies. Preeclampsia 
also is known by a disorder of extensive endothelial 
function, starting with placental cytotrophoblast 
invasion, which can lead to clinical hypertension [1].
 
In pregnancy, there is a normal change in 
blood pressure due to hemodynamic changes to allow 
the exchange of blood and nutrients to the fetus. This 
circulation change usually occurs in the first trimester 
of pregnancy, during trophoblast implantation. The 
vascularisation changes of the decidua make the 
capacity of blood vessels that are initially high 
resistance with low capacity to be low resistance with 
high capacity, and this change will disrupt oxygen 
supply to the placenta. Increasing gestational age, the 
fetus will need a higher oxygen supply, but because 
vasoconstriction that occurs in the fetal blood vessels 
causes compensation to increase maternal blood 
pressure [2].
 
Curcumin which is the main component in 
curcuminoid theoretically acts as an anti-inflammatory 
agent by inhibiting NF-κβ activation, which is an 
important regulator of COX-2 expression [2]. 
Curcumin has been studied as a therapeutic agent for 
various types of diseases, the effect of curcumin as 
antiangiogenic, antioxidant and anti-inflammatory 
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affects several biological markers that are thought to 
play a role in the pathogenesis of preeclampsia such 
as IL-10 and COX-2 so that there is an improvement 
in women with preeclampsia.  
This study was designed to prove that the 
administration of curcumin can change IL-10 and 
COX-2 levels and perioperative VAS in preeclamptic 
patients undergoing cesarean section under spinal 
anaesthesia. 
 
 
Material and Methods 
 
This is an experimental double-blind study 
with the type of pre and post-test control group 
design. Patients who diagnosed with preeclampsia 
and met the inclusion criteria, then divided into 2 
groups which received drugs containing curcumin (as 
a treatment) and other group received placebo (as a 
control). The study was done at H Adam Malik 
Hospital, Medan, USU Hospital, RSUD dr. Pirngadi 
Medan, Hospital Putri Hijau Medan and Sundari 
General Hospital Medan, as a network Hospital for 
Medical Faculty of USU. 
Pregnant preeclampsia women, with age 
range from 19-40 years, single pregnancy with a term 
of gestational age and planned for caesarean section 
with subarachnoid block regional anaesthesia 
techniques were included to inclusion criteria. 
Meanwhile, samples who had a systemic infection, 
chronic diseases (kidney disease & hypertension, 
diabetes mellitus) were the exclusion criteria for this 
study. Massive bleeding, patients who needed a 
hysterectomy, patients who had cardiac arrest and 
breathing problem during operation and prolong 
operation time were excluded from the study. 
Fifty pregnant women were included in this 
study and had been informed about the study divided 
into two groups, one group received curcumin as a 
treatment group, and the other group received 
placebo as a control group. Three samples were 
excluded from this study because after blood samples 
were taken, the result was unreadable. 
All samples who diagnosed with preeclampsia 
was being informed about the study after informed 
consent accepted blood were taken to examine all the 
biomarkers (T0), 90 minutes (T1) after the drugs 
given, second blood samples were taken for the 
second examination. Then sectio caesarean operation 
was done under spinal anaesthesia. 12 hours (T2) 
after the drugs are given another blood samples were 
taken to examine the biomarkers. All samples 
received Magnesium Sulphate based on 
preeclampsia’s guidelines therapy. 
 
 
Results  
 
In this study, 47 samples were reported and 
divided into 2 groups, treatment groups (23 samples) 
and control groups (24 samples). The difference in 
serum COX-2 levels after being given curcumin is 
presented in Table 1. 
Table 1: Differences in serum COX-2 levels after being given 
curcumin 
 
 
Based on Table 1, comparison of COX-2 
results in both groups at T0, T1 and T2 showed no 
significant differences indicated by the median values 
in the two groups that were not too far different and 
the p-values indicating values greater than 0.05. That 
is, from T0, T1 to T2 in both groups (control and 
treatment) no significant COX-2 levels were found. 
Based on the value of COX-2 changes from 
T0 to T2 in each group indicated by the p-value in the 
Friedman test. The Friedman test results in the control 
group produced a p-value of 0.325, which was greater 
than 0.05, indicating that in the control group, there 
was no significant change in COX-2 levels from T0 to 
T2. Similarly, in the treatment group, a p-value of 
0.438 which was greater than 0.05 showed that in the 
control group, there was no significant change in 
COX-2 levels from T0 to T2 (Figure 1). 
 
Figure 1: Differences in serum COX-2 levels after being given 
curcumin 
 
The changes in serum IL-10 levels presented 
in Table 2, comparison of IL-10 results in both groups 
at T0, T1 and T2 showed no significant differences 
indicated by the median values in the two groups that 
were not too far different and the p-values indicating 
values greater than 0.05. That is, from T0, T1 to T2 in 
both groups (control and treatment) there was no 
significant IL-10 level found. 
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Table 2: Differences in serum IL-10 levels after being given 
curcumin 
 
 
Based on the value of IL-10 changes from T0 
to T2 in each group indicated by the p-value in the 
Friedman test. The Friedman test results in the control 
group produced a p-value of 0.582, which was greater 
than 0.05, indicating that in the control group, there 
was no significant change in IL-10 levels from T0 to 
T2. Similarly, in the treatment group, a p-value of 
0.296 which was greater than 0.05 showed that in the 
control group, there was no significant change in IL-10 
levels from T0 to T2 (Figure 2). 
 
Figure 2: Differences in serum IL-10 levels after being given 
curcumin 
 
Differences time by time can be seen in Table 
3. There were no significant differences in IL-10 p-
values (T0-T1 = 0.051, T0-T2 = 0.476 and T1-T2 = 
0.317) and in COX-2 (T0-T1 = 0.437, T0-T2 = 0.890 
and T1-T2 = 0.191) both in control and treatment 
groups.  
Table 3: Differences in serum IL – 10 and COX-2 levels between 
observations  
 
 
 
 
Discussion 
 
To our knowledge, our research was the first 
to assess the effect of curcumin in preeclampsia 
patients. So, the dosage that given was only once 
daily and only 100 mg of curcumin, although many 
studies used higher dosage in cancer or 
neurodegenerative patients.  
IL-10 was first reported by Mosmann et al. as 
Cytokine Synthesis Inhibitory Factor (CSIF) as a 
protein with the ability to inhibit the activity of Th-1 
type cells. CSIF is considered as the main factor that 
defines the difference between Th-1 and Th-2 type T 
cells because CSIF cuts T-cell activation. Although 
initially defined as Th-2 cell products, these cytokines 
have now been shown to be produced by various 
types of cells, including immune and non-immune 
cells. The report also shows that one way of 
regulating IL-10 is through a feedback loop that 
inhibits excessive inflammation [3].
 
IL-10 in humans is a homodimeric protein that 
is sensitive to monomeric acid with a molecular weight 
of 18.5 kDa which is encoded on chromosome 1 in 
mice and humans. IL-10 mice and human IL-10 are 
sufficiently conserved in their amino acid sequences 
to share 73% homology and are especially different in 
human N-glycosylation sites with IL-10 [4].
 
The serum and amount of placental IL-10 
have been reported to increase in normal 
pregnancies. Sowmya et al., [5],
 
in their study 
mentioned that variations in IL-10 production are 
largely genetically determined, which is mainly related 
to genetic variation in the study area that linked to the 
level of transcription. A study by Benian et al., [6],
 
in 
the Istanbul population, have shown levels of IL-10 in 
plasma and IL-10 in the placenta. In contrast, Madazli 
et al., [7], reported an increase in IL-10 levels in 
maternal plasma of preeclamptic patients compared 
with normotensive women in the Istanbul population. 
Mansouri et al., [8], conducted a study on serum 
samples of preeclampsia patients and control subjects 
and revealed no significant changes in the 
examination. On the other hand, Makris et al., [9],
 
showed that IL-10 promoter genotypes might not play 
an important role in circulating IL-10 levels but 
showed effects on IL-10 placental levels in the study 
population. This result suggests that IL-10 plays an 
important role [5].
 
There is increasing evidence that 
inflammation with COX-2 expression plays a key role 
in preeclampsia, so increasing the expression of 
neutrophils from COX-2 is an important finding 
regarding the pathophysiology of preeclampsia. 
Increased COX-2 expression seems to be 
widespread. COX-2 is increased in the placenta of 
women with preeclampsia where the expression is 
associated with an increase in thromboxane 
production. The placenta from preeclamptic women 
produces more thromboxane and less prostacyclin 
than the placenta obtained from normal pregnant 
women. Thromboxane is a strong vasoconstrictor, 
whereas prostacyclin is a strong vasodilator, so this 
imbalance contributes to reduced uteroplacental blood 
flow in preeclampsia [10].
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Curcumin modulates the inflammatory 
response by reducing the activity of the 
cyclooxygenase-2 (COX-2) enzyme, lipoxygenase, 
and inducible nitric oxide synthase (iNOS); inhibits the 
production of inflammatory cytokines tumour necrosis 
factor-alpha (TNF-a), interleukin (IL) -1, -2, -6, -8, and 
-12, monocyte chemoattractant protein (MCP) and 
protein inhibitory migration also decreases mitogen-
regulation activated and Janus kinases. (Julie, 2009). 
Curcumin is thought to be able to directly act on 
oxygenation of arachidonic acid or nitrogen-reactive 
species due to its antioxidant ability. Curcumin can 
modulate COX-2 via iNOS [11].
 
Inhibition of COX-2 
and iNOS results from suppression of curcumin in NF-
κ activation [12].
 
COX-2 expression regulation occurs not only 
at the transcriptional level but also at the post-
transcriptional level. The main function of COX-2 is to 
mediate the conversion of arachidonic acid into 
prostaglandin H2, which is then converted to various 
PGs with various syntheses. The Study reported that 
COX-2 provides action on cell function, including 
modulation of cell proliferation and cell migration. 
Other researchers have reported the role of COX-2 in 
angiogenesis, seen by using a modified vascular 
endothelial growth factor (VEGF) as an endpoint. 
However, in the human placenta, the results are 
inconsistent, with several studies showing placental 
COX-2 levels not to differ between normal 
pregnancies and preeclamptic pregnancies. Others 
found that COX-2 levels in preeclamptic women were 
reduced as measured by immunoblotting, and this 
effect has been linked to oxidative stress [13].
 
 
 
References 
  
1. Wang A, Rana S, Karumanchi APreeclampsia: The Role Of 
Angiogenic Factors In Its Pathogenesis. Int Union Physiol Soc. 
2008. 
2. Teelkien V, Panerai B, Haeri S, Griffien C, Zaeman G, Belfort A. 
Cerebral Autoregulation In Normal Pregnancy And Preeclampsia. 
American College Of Obstetricians And Gynecologists. 2013; 
122(5):1064-1069. 
https://doi.org/10.1097/AOG.0b013e3182a93fb5 PMid:24104783 
 
3. Zimmerman MA, Reznikov LL, Raeburn CD, Selzman CH. 
Interleukin-10 attenuates the response to vascular injury1, 2. 
Journal of Surgical Research. 2004; 121(2):206-13. 
https://doi.org/10.1016/j.jss.2004.03.025 PMid:15501460 
 
4. Cheng SB, Sharma S. Interleukin‐10: a pleiotropic regulator in 
pregnancy. Am J Reprod Immunol: 2015; 73(6):487-500. 
https://doi.org/10.1111/aji.12329 PMid:25269386 
PMCid:PMC4382460 
 
5. Sowmya S, Ramaiah A, Sunitha T, Nallari P, Jyothy A, 
Venkateshwari A. Role of IL-10-819 (t/c) promoter polymorphism in 
preeclampsia. Inflammation. 2014; 37(4):1022-7. 
https://doi.org/10.1007/s10753-014-9824-2 PMid:24477695 
 
6. Benian A, Madazlı R, Aksu F, Uzun H, Aydın S. Plasma and 
placental levels of interleukin-10, transforming growth factor-β1, 
and epithelial-cadherin in preeclampsia. Obstetrics & Gynecology. 
2002; 100(2):327-31. https://doi.org/10.1097/00006250-
200208000-00021 PMid:12151158 
 
7. Madazli R, Aydin S, Uludag S, Vildan O, Tolun N. Maternal 
plasma levels of cytokines in normal and preeclamptic pregnancies 
and their relationship with diastolic blood pressure and fibronectin 
levels. Acta obstetricia et gynecologica Scandinavica. 2003; 
82(9):797-802. https://doi.org/10.1034/j.1600-0412.2003.00206.x 
PMid:12911439 
 
8. Mansouri R, Akbari F, Vodjgani M, Mahboudi F, Kalantar F, 
Mirahmadian M. Serum cytokines profiles in Iranian patients with 
preeclampsia. Iranian Journal of Immunology. 2007; 4(3):179-85. 
 
9. Makris A, Xu B, Yu B, Thornton C, Hennessy A. Placental 
deficiency of interleukin-10 (IL-10) in preeclampsia and its 
relationship to an IL10 promoter polymorphism. Placenta. 2006; 
27(4-5):445-51. https://doi.org/10.1016/j.placenta.2005.05.003 
PMid:16026832 
 
10. Bachawaty T, Washington SL, Walsh SW. Neutrophil 
expression of cyclooxygenase 2 in preeclampsia. Reprod Sci. 
2010; 17(5):465-70. https://doi.org/10.1177/1933719110361960 
PMid:20220108 PMCid:PMC2850955 
 
11. Rao CV. Regulation of Cox and Lox by Curcumin. The 
Molecular Targets and Therapeutic Uses of Curcumin in Health 
and Disease. Hal. 2007; 213-226. https://doi.org/10.1007/978-0-
387-46401-5_9 PMid:17569213 
 
12. Surh YJ, Chun KS, Cha HH, Han SS, Keum YS, Park KK, Lee 
SS. Molecular mechanisms underlying chemopreventive activities 
of anti-inflammatory phytochemicals: down-regulation of COX-2 
and iNOS through suppression of NF-κB activation. Mutation 
Research/Fundamental and Molecular Mechanisms of 
Mutagenesis. 2001; 480:243-68. https://doi.org/10.1016/S0027-
5107(01)00183-X 
 
13. Zhang D, Chang X, Bai J, Chen ZJ, Li WP, Zhang C. The study 
of cyclooxygenase 2 in human decidua of preeclampsia. Biology of 
reproduction. 2016; 95(3):56-1. 
https://doi.org/10.1095/biolreprod.115.138263 PMid:27465134 
 
 
